RE
ALXN

RBC Europe’s Alexion Pharmaceuticals ALXN Stock Holding History

RBC Europe’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-475
Closed -$53.3K – 1129
2020
Q2 		$53.3K Buy
+475
New +$50.4K ﹤0.01% 433
2019
Q3 		– Sell
-60
Closed -$7.86K – 1088
2019
Q2 		$7.86K Hold
60
– – ﹤0.01% 851
2019
Q1 		$8.11K Buy
+60
New +$7.46K ﹤0.01% 857
2018
Q2 		– Sell
-39
Closed -$4.35K – 1190
2018
Q1 		$4.35K Hold
39
– – ﹤0.01% 969
2017
Q4 		$4.66K Hold
39
– – ﹤0.01% 964
2017
Q3 		$5.47K Buy
+39
New +$5.3K ﹤0.01% 938

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RBC Europe's ALXN Position: Q3 2020 in Review

RBC Europe sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 475 shares — an estimated $53.3K sold.

RBC Europe first reported a position in ALXN in Q3 2017 and held it in 6 quarters. The position peaked at $53.3K in Q2 2020. 709 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • RBC Europe reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • RBC Europe sold 475 Alexion Pharmaceuticals shares in Q3 2020, an estimated $53.3K.
  • RBC Europe first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 6 quarters.
  • RBC Europe's Alexion Pharmaceuticals position peaked at $53.3K in Q2 2020.
  • 709 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on RBC Europe's 13F filing for Q3 2020, filed 9 Nov 2023.